1. 806PRelationship between apalutamide (APA) exposure and metastasis-free survival (MFS) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) from SPARTAN. (23rd October 2018) Authors: Smith, M R; Perez-Ruixo, C; Ackaert, O; Ouellet, D; Chien, C; Uemura, H; Olmos, D; Mainwaring, P N; Lee, J Y; Yu, M K; Perez-Ruixo, J-J; Small, E J Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Apalutamide and overall survival in non-metastatic castration-resistant prostate cancer. (27th September 2019) Authors: Small, E J; Saad, F; Chowdhury, S; Oudard, S; Hadaschik, B A; Graff, J N; Olmos, D; Mainwaring, P N; Lee, J Y; Uemura, H; De Porre, P; Smith, A A; Zhang, K; Lopez-Gitlitz, A; Smith, M R Journal: Annals of oncology Issue: Volume 30:Number 11(2019) Page Start: 1813 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Circulating tumour cell increase as a biomarker of disease progression in metastatic castration-resistant prostate cancer patients with low baseline CTC counts. (7th May 2018) Authors: Lorente, D; Olmos, D; Mateo, J; Dolling, D; Bianchini, D; Seed, G; Flohr, P; Crespo, M; Figueiredo, I; Miranda, S; Scher, H I; Terstappen, L W M M; de Bono, J S Journal: Annals of oncology Issue: Volume 29:Number 7(2018) Page Start: 1554 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Dissecting prostate carcinogenesis through ETS gene rearrangement studies: implications for anticancer drug development. Issue 8 (21st May 2008) Authors: Attard, G; Ang, J E; Olmos, D; de Bono, J S Journal: Journal of clinical pathology Issue: Volume 61:Issue 8(2008) Page Start: 891 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. LBA8PROfound: Phase III study of olaparib versus enzalutamide or abiraterone for metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene alterations. (24th November 2019) Authors: Sandhu, S K; Hussain, M; Mateo, J; Fizazi, K; Saad, F; Shore, N; Chi, K; Sartor, O; Agarwal, N; Olmos, D; Thiery-Vuillemin, A; Twardowski, P; Mehra, N; Goessl, C; Kang, J; Burgents, J; Wu, W; Kohlmann, A; Adelman, C; de Bono, J Journal: Annals of oncology Issue: Volume 30(2019)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗